Kodiak Sciences Inc. (NASDAQ:KOD) Receives Consensus Rating of “Moderate Buy” from Brokerages

Kodiak Sciences Inc. (NASDAQ:KOD) has been assigned an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $28.2857.

A number of research firms recently commented on KOD. Chardan Capital reiterated a “neutral” rating and issued a $14.00 target price on shares of Kodiak Sciences in a research report on Monday, November 17th. UBS Group assumed coverage on Kodiak Sciences in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $38.00 target price on shares of Kodiak Sciences in a research report on Tuesday, February 10th.

Kodiak Sciences Stock Performance

Shares of NASDAQ KOD opened at $26.80 on Monday. The company has a market cap of $1.42 billion, a P/E ratio of -6.50 and a beta of 2.61. Kodiak Sciences has a 52-week low of $1.92 and a 52-week high of $31.18. The firm’s fifty day moving average is $26.07 and its two-hundred day moving average is $19.73.

Insider Transactions at Kodiak Sciences

In other Kodiak Sciences news, Director Bros. Advisors Lp Baker acquired 2,608,696 shares of the stock in a transaction on Thursday, December 18th. The stock was acquired at an average price of $23.00 per share, for a total transaction of $60,000,008.00. Following the completion of the transaction, the director directly owned 18,358,772 shares of the company’s stock, valued at $422,251,756. This trade represents a 16.56% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 45.90% of the stock is currently owned by insiders.

Institutional Trading of Kodiak Sciences

A number of institutional investors have recently bought and sold shares of KOD. EverSource Wealth Advisors LLC boosted its stake in Kodiak Sciences by 1,221.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock worth $28,000 after buying an additional 916 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Kodiak Sciences in the 4th quarter worth about $29,000. Headlands Technologies LLC boosted its stake in shares of Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock worth $30,000 after purchasing an additional 5,815 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Kodiak Sciences during the 4th quarter worth about $72,000. Finally, Strs Ohio bought a new position in Kodiak Sciences during the 4th quarter valued at about $87,000. 89.06% of the stock is currently owned by institutional investors.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.